General MedicationsORALStandard
NINLARO
IXAZOMIB CITRATE
Standard Dose
EQ 4MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview NINLARO is listed in Drugs@FDA under application 208462 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient IXAZOMIB CITRATE Form and strength CAPSULE;ORAL - EQ 4MG BASE Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2024-07-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview NINLARO is listed in Drugs@FDA under application 208462 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient IXAZOMIB CITRATE Form and strength CAPSULE;ORAL - EQ 4MG BASE Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2024-07-01 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.